ATS
HQL

Ashton Thomas Securities’s abrdn Life Sciences Investors HQL Stock Holding History

Ashton Thomas Securities’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,817
Closed -$148K – 669
2024
Q3 		$148K Buy
+9,817
New +$149K 0.03% 289

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
AIA
Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Ashton Thomas Securities's HQL Position: Q4 2024 in Review

Ashton Thomas Securities sold out of abrdn Life Sciences Investors (HQL) in Q4 2024, closing a stake of 9,817 shares — an estimated $148K sold.

Ashton Thomas Securities first reported a position in HQL in Q3 2024 and held it in 1 quarter. The position peaked at $148K in Q3 2024. 72 funds tracked by Wall St. Rank hold HQL as of Q4 2024.

  • Ashton Thomas Securities reported no remaining abrdn Life Sciences Investors position as of Q4 2024 after selling out during the quarter.
  • Ashton Thomas Securities sold 9,817 abrdn Life Sciences Investors shares in Q4 2024, an estimated $148K.
  • Ashton Thomas Securities first reported a position in abrdn Life Sciences Investors in Q3 2024 and held it in 1 quarter.
  • Ashton Thomas Securities's abrdn Life Sciences Investors position peaked at $148K in Q3 2024.
  • 72 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2024.

Based on Ashton Thomas Securities's 13F filing for Q4 2024, filed 11 Feb 2025.